Abstract
In early 2020, the first US and Canadian cases of the novel severe acute respiratory syndrome coronavirus 2 infection were detected. In the ensuing months, there has been rapid spread of the infection. In March 2020, in response to the virus, state/provincial and local governments instituted shelter-in-place orders, and nonessential ambulatory care was significantly curtailed, including allergy/immunology services. With rates of new infections and fatalities potentially reaching a plateau and/or declining, restrictions on provision of routine ambulatory care are lifting, and there is a need to help guide the allergy/immunology clinician on how to reinitiate services. Given the fact that coronavirus disease 2019 will circulate within our communities for months or longer, we present a flexible, algorithmic best-practices planning approach on how to prioritize services, in 4 stratified phases of reopening according to community risk level, as well as highlight key considerations for how to safely do so. The decisions on what services to offer and how fast to proceed are left to the discretion of the individual clinician and practice, operating in accordance with state and local ordinances with respect to the level of nonessential ambulatory care that can be provided. Clear communication with staff and patients before and after all changes should be incorporated into this new paradigm on continual change, given the movement may be forward and even backward through the phases because this is an evolving situation.
Original language | English (US) |
---|---|
Pages (from-to) | 2125-2134 |
Number of pages | 10 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 8 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2020 |
Keywords
- Allergic rhinitis
- Allergy
- Angioedema
- Asthma
- Atopic dermatitis
- COVID-19
- Food allergy
- Immunotherapy
- Personal protective equipment
- Primary immunodeficiency
- SARS-CoV-2
- Urticaria
ASJC Scopus subject areas
- Immunology and Allergy
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services. / Searing, Daniel A.; Dutmer, Cullen M.; Fleischer, David M. et al.
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, No. 7, 01.07.2020, p. 2125-2134.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services
AU - Searing, Daniel A.
AU - Dutmer, Cullen M.
AU - Fleischer, David M.
AU - Shaker, Marcus S.
AU - Oppenheimer, John
AU - Grayson, Mitchell H.
AU - Stukus, David
AU - Hartog, Nicholas
AU - Hsieh, Elena W.Y.
AU - Rider, Nicholas L.
AU - Vander Leek, Timothy K.
AU - Kim, Harold
AU - Chan, Edmond S.
AU - Mack, Doug
AU - Ellis, Anne K.
AU - Abrams, Elissa M.
AU - Bansal, Priya
AU - Lang, David M.
AU - Lieberman, Jay
AU - Golden, David BK
AU - Wallace, Dana
AU - Portnoy, Jay
AU - Mosnaim, Giselle
AU - Greenhawt, Matthew
N1 - Funding Information: M.G. is supported by the Agency for Healthcare Research and Quality (grant no. 5K08HS024599-02)Conflicts of interest: D. M. Fleischer reports receiving institutional research funding from DBV Technologies and Aimmune Therapeutics; has served as a consultant and received personal fees from DBV Technologies, AllerGenis, Aquestive, Aravax, DOTS Technology, Intrommune, Genentech, and Nasus; is a nonpaid member of the Scientific Advisory Council for the National Peanut Board; and is a nonpaid member of clinical advisory boards for Food Allergy Research & Education and Food Allergy and Anaphylaxis Connectivity Team. M. S. Shaker is a member of the Joint Taskforce on Allergy Practice Parameters; has a family member who is CEO of Altrix Medical; and serves on the editorial boards of the Journal of Food Allergy and the Annals of Allergy, Asthma, and Immunology. J. Oppenheimer reports receiving research support/adjudication from AstraZeneca, GlaxoSmithKline, Sanofi, and Novartis; is a consultant for GlaxoSmithKline, AstraZeneca, and Sanofi; is an associate editor for the Annals of Allergy, Asthma, and Immunology, AllergyWatch; is section editor for Current Opinion of Allergy; receives royalties from UpToDate; is Board Liaison American Board of Allergy and Immunology for American Board of Internal Medicine; and is a member of the Joint Taskforce on Allergy Practice Parameters. M. H. Grayson is a medical advisory board participant for Aimmune, DBV, and Genzyme; is Director and Treasurer of the ABAI; is an associate editor of the Annals of Allergy, Asthma, and Immunology; is Chair of the Medical Scientific Council of the Asthma and Allergy Foundation of America; and is a member of the Scientific Advisory Committee of the American Lung Association and the American Academy of Allergy, Asthma & Immunology (AAAAI) COVID-19 Task Force. D. Stukus is a consultant for DBV Therapeutics, Before Brands, and Abbott Nutrition and is a member of the AAAAI COVID-19 Task Force. N. Hartog is a speaker for and a member of the advisory board of Horizon Pharmaceuticals; is a speaker for Takeda; and is on the Orchard Therapeutics advisory board. E. W. Y. Hsieh is supported by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant no. K23AR070897), the Boettcher Foundation Webb-Waring Biomedical research grant, the Childhood Arthritis and Rheumatology Research Alliance large grant, the Jeffrey Modell Foundation Translational Award, and Takeda Pharmaceuticals. N. L. Rider is a consultant and a member of the scientific advisory boards for Horizon Therapeutics, CSL Behring, and Takeda Pharmaceuticals; receives royalties from Kluwer Wolters; is a topic contributor for UpToDate; and has received grant funding from the Jeffrey Model Foundation. T. K. Vander Leek has served on advisory boards for Aralez and Pediapharm and has served on speaker bureaus for and received honoraria from Aralez, Pediapharm, and Pfizer. H. Kim has served on speakers' bureau and advisory boards for AstraZeneca, Aralez, Boehringer Ingelheim, CSL Behring, Kaleo, Merck, Mylan, Novartis, Pediapharm, Sanofi, Shire, and Teva and has received research funding from AstraZeneca, Shire, Sanofi, and Novartis. E. S. Chan has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, and AllerGenis; is a member of the healthcare advisory board for Food Allergy Canada; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; and was co-lead of the Canadian Society of Allergy and Clinical Immunology oral immunotherapy guidelines. D. Mack is a member of the Board of Directors for the Canadian Society of Allergy and Clinical Immunology; serves on the Editorial Board of the Journal of Food Allergy; has provided consultation and speaker services for Pfizer, Aimmune, Merck, Covis, and Pediapharm; and has been part of an advisory board for Pfizer and Bausch Health. A. K. Ellis has participated in advisory boards for ALK-Abell?, AstraZeneca, Aralez, Bausch Health, Circassia Ltd, GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm, and Pfizer; has been a speaker for ALK, Aralez, AstraZeneca, Boerhinger-Ingelheim, CACME, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, The ACADEMY, and Takeda; her institution has received research grants from Bayer LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron, and Sanofi; and has served as an independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc, and Regeneron in the past. E. M. Abrams is a collaborator with the Institute for Health Metrics and Evaluation; is on the National Advisory Board for Food Allergy Canada; and is on the National Food Allergy Action Plan Action Steering Team for Food Allergy Canada. P. Bansal has served on the advisory boards for Genentech, Regeneron, Kaleo, AstraZeneca, ALK, Shire, Takeda, Pharming, CSL Behring, and Teva; is a speaker for AstraZeneca, Regeneron, ALK, Takeda, Shire, CSL Behring, Takeda, and Pharming; has served as an independent consultant for ALK, AstraZeneca, and Exhale; and is a member of the AAAAI COVID-19 Task Force. D. M. Lang is on the Editorial Board for Allergy and Asthma Proceedings; is topic editor for DynaMed; is an associate editor for J Asthma; and is delegate to National Quality Forum representing the AAAAI. J. Lieberman has received research support (money to institution) from DBV, Aimmune, and Regeneron; is on the advisory boards for DBV, Genentech, and Covis; and has provided consulting for Kaleo. D. B. K. Golden has received financial support from Aquestive, Sandoz, ALK-Abell?, Genentech, Stallergenes Greer, and UpToDate. D. Wallace has received financial support from Mylan, Kaleo, Optinose, ALK, Bryan, and Sanofi. J. Portnoy has received financial support from Thermofisher, Kaleo, Teva, Novartis, Hycor, and Boehringer Ingelheim. G. Mosnaim has received research grant support from AstraZeneca and GlaxoSmithKline; currently receives research grant support from Propeller Health; owned stock in Electrocore; and served as a consultant and/or member of a scientific advisory board for GlaxoSmithKline, Sanofi-Regeneron, Teva, Novartis, Astra Zeneca, Boehringer Ingelheim, and Propeller Health. M. Greenhawt is supported by the Agency for Healthcare Research and Quality (grant no. 5K08HS024599-02); is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, GlaxoSmithKline, Merck, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, AllerGenis, Aravax, and Monsanto; is a member of the Scientific Advisory Council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy, Asthma, and Immunology, and the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: M.G. is supported by the Agency for Healthcare Research and Quality (grant no. 5K08HS024599-02 ) Publisher Copyright: © 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/7/1
Y1 - 2020/7/1
N2 - In early 2020, the first US and Canadian cases of the novel severe acute respiratory syndrome coronavirus 2 infection were detected. In the ensuing months, there has been rapid spread of the infection. In March 2020, in response to the virus, state/provincial and local governments instituted shelter-in-place orders, and nonessential ambulatory care was significantly curtailed, including allergy/immunology services. With rates of new infections and fatalities potentially reaching a plateau and/or declining, restrictions on provision of routine ambulatory care are lifting, and there is a need to help guide the allergy/immunology clinician on how to reinitiate services. Given the fact that coronavirus disease 2019 will circulate within our communities for months or longer, we present a flexible, algorithmic best-practices planning approach on how to prioritize services, in 4 stratified phases of reopening according to community risk level, as well as highlight key considerations for how to safely do so. The decisions on what services to offer and how fast to proceed are left to the discretion of the individual clinician and practice, operating in accordance with state and local ordinances with respect to the level of nonessential ambulatory care that can be provided. Clear communication with staff and patients before and after all changes should be incorporated into this new paradigm on continual change, given the movement may be forward and even backward through the phases because this is an evolving situation.
AB - In early 2020, the first US and Canadian cases of the novel severe acute respiratory syndrome coronavirus 2 infection were detected. In the ensuing months, there has been rapid spread of the infection. In March 2020, in response to the virus, state/provincial and local governments instituted shelter-in-place orders, and nonessential ambulatory care was significantly curtailed, including allergy/immunology services. With rates of new infections and fatalities potentially reaching a plateau and/or declining, restrictions on provision of routine ambulatory care are lifting, and there is a need to help guide the allergy/immunology clinician on how to reinitiate services. Given the fact that coronavirus disease 2019 will circulate within our communities for months or longer, we present a flexible, algorithmic best-practices planning approach on how to prioritize services, in 4 stratified phases of reopening according to community risk level, as well as highlight key considerations for how to safely do so. The decisions on what services to offer and how fast to proceed are left to the discretion of the individual clinician and practice, operating in accordance with state and local ordinances with respect to the level of nonessential ambulatory care that can be provided. Clear communication with staff and patients before and after all changes should be incorporated into this new paradigm on continual change, given the movement may be forward and even backward through the phases because this is an evolving situation.
KW - Allergic rhinitis
KW - Allergy
KW - Angioedema
KW - Asthma
KW - Atopic dermatitis
KW - COVID-19
KW - Food allergy
KW - Immunotherapy
KW - Personal protective equipment
KW - Primary immunodeficiency
KW - SARS-CoV-2
KW - Urticaria
UR - http://www.scopus.com/inward/record.url?scp=85085753408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085753408&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.05.012
DO - 10.1016/j.jaip.2020.05.012
M3 - Article
C2 - 32450236
AN - SCOPUS:85085753408
SN - 2213-2198
VL - 8
SP - 2125
EP - 2134
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 7
ER -